For more than a century, a true insulin pill has been one of medicine’s most stubborn “dream” projects.
Now, researchers at Kumamoto University in Japan say they have built a drug delivery platform that helps insulin cross the intestinal wall, producing strong glucose-lowering effects in diabetic mice with pharmacological bioavailability of about 33% to 41% compared with subcutaneous injection.
That matters because the need is enormous and growing. The World Health Organization estimates 830 million people were living with diabetes in 2022, and the International Diabetes Federation puts the adult burden at 589 million people in 2024, with major health and economic costs that spill into everyday life, from clinic visits to the monthly pharmacy run.
Why insulin still comes with needles
Insulin is a protein, and your digestive system is basically designed to shred proteins into pieces before they can do anything useful. That is one reason oral insulin has repeatedly failed in the real world, even when it looked promising on paper.
The second problem is the intestinal wall itself, which does not naturally “welcome” large molecules like insulin into the bloodstream. In practical terms, that means most people who need insulin still rely on injections or pumps, even though the routine can be exhausting over the long haul.
The DNP peptide, explained simply
The Kumamoto team’s core idea is a small-intestine-permeable cyclic peptide known as the DNP peptide. Think of it less as “oral insulin” and more as a new way to escort insulin across a barrier that usually blocks it.
Associate Professor Shingo Ito, who led the work, framed it in human terms rather than chemistry jargon, saying, “Insulin injections remain a daily burden for many patients.” The researchers argue their peptide-based platform offers “a new route” for oral delivery, which is the part that has kept scientists stuck for decades.
Two strategies that reached the same goal
The researchers tested two approaches, and both were designed to solve the same bottleneck: getting insulin through the intestine without destroying it. One was a mixing method where a modified “D-DNP-V peptide” was mixed with zinc-stabilized insulin hexamers, and the other was a conjugation method that directly linked the DNP peptide to insulin using click chemistry.
In multiple diabetic mouse models, including chemically induced STZ mice and a genetic model, the team reports that oral dosing rapidly reduced blood glucose levels, with once-daily dosing maintaining control for three consecutive days.
Importantly, the conjugated version produced glucose-lowering effects comparable to the mixing approach, which supports the claim that the peptide is doing real transport work rather than acting as a fluke additive.
The efficiency number that is turning heads
The headline figure is pharmacological bioavailability of about 33% to 41% relative to subcutaneous injection. In the oral drug world, that is the kind of number that makes scientists and investors stop scrolling, because many oral macromolecule efforts struggle to reach anything close to that range.
It also tackles a practical deal breaker: dose size. As ScienceDaily’s summary of the university’s materials notes, previous oral insulin concepts often demanded extremely high doses, sometimes more than ten times higher than injections, which is a nonstarter for cost, safety, and manufacturing.
Convenience is only part of the story
Yes, a pill could remove a lot of friction from daily life. Anyone who has had to time meals, manage supplies, and find a discreet place to dose knows that treatment burden is not an abstract concept – it is something that follows you into work meetings, road trips, and busy family evenings.
There is also a physiological argument that keeps coming up in oral insulin research. Reviews note that oral insulin absorption can be more “natural” in the sense that it reaches the liver through portal circulation, better mimicking how insulin normally moves in the body compared with peripheral injection.
That potential advantage is not guaranteed here, but it is one reason scientists keep pushing toward oral delivery instead of giving up.
A big business prize with real-world constraints
Diabetes is not just a medical condition – it is an economic force. The IDF estimates diabetes drove at least $1 trillion in health expenditure in 2024, a figure that helps explain why every incremental improvement in delivery and adherence draws intense attention.
On the market side, estimates vary, but one recent industry analysis pegged the global insulin market at about $29.2 billion in 2025.
If an oral insulin platform ever proves reliable in humans, it could reshape competition around formulations, manufacturing partnerships, and even pharmacy channel strategies, though it could also introduce new pricing pressure if the tech is costly to scale.
What still has to be proven before any human pill
For now, this is still an animal study, and that should temper expectations. Mouse intestines are not human intestines, eating patterns vary wildly, and even small swings in absorption can mean the difference between stable control and a dangerous low.
Kumamoto University says the team is moving toward translational studies, including evaluation in large animal models and human intestinal systems, which is the right direction but not the same as a clinical trial in people. In other words, the science looks encouraging, but the road to something you can actually pick up at a pharmacy is still long.
The press release was published on Kumamoto University.
